Combination of radiotherapy and gemcitabine - Evaluation of clinical data based on experimental results;Kombination von radiotherapie und gemcitabine. Bewertung der klinischen daten auf der basis experimenteller erkenntnisse

Strahlentherapie und Onkologie

Volumn 178, Issue 2, 2002, Pages 59-70

  Mose, Stephan ^a   Class, Reiner ^b   Weber, Hans Walter ^b   Oszvald, Ági ^a   Rahn, Angelika ^a   Brady, Luther W ^b   Bottcher H D ^a  

^a GOETHE UNIVERSITY   (Germany)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Gemcitabine; Literature review; Radiation enhancement; Radiochemotherapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CELL DNA; GEMCITABINE; NUCLEOSIDE DERIVATIVE;

ANIMAL MODEL; APOPTOSIS; CANCER; CELL CYCLE; CLINICAL RESEARCH; CLINICAL TRIAL; DNA REPAIR; DNA SYNTHESIS INHIBITION; DOSE TIME EFFECT RELATION; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION INJURY; RADIOSENSITIZATION; REVIEW;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 0036173184     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-002-0879-x     Document Type: Review

References (83)

1. Gemcitabine - A safety review
2. Alternating/concomitant gemcitabine (Gem), cisplatin (CDDP) and radio-therapy (RT) in advanced squamous cell carcinoma of the head and neck (SCC-HN)
3. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
4. Twice-weekly gemcitabine and con-current thoracic radiotherapy - A phase I/II study in patients with advanced non-small cell Lung cancer
5. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
6. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems
7. A phase I trial of simultaneous gemcitabine/cisplatin and radiotherapy for patients with localized advanced pancreatic adenocarcinoma
8. The role of gemcitabine in the treatment of other tumours
9. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization
10. Weekly low dose continuous infusion of gemcitabine as a salvage therapy protocol in solid tumors
11. Zukünftig nur noch simultane radiochemotherapie in der onkologie?
12. Toxicity of a 24-hour infusion of gemcitabine (Gem) in biliary tract and pancreatic cancer
13. Radiation (RT) concurrent with low dose gemcitabine (Gem) for head and neck cancer: Interim results of a phase I study
14. Phase I trial of radiation concurrent with low-dose gemcitabine for head and neck cancer: High mucosal and pharyngeal toxicity
15. A phase II study of gemcitabine (Gem) combined with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer
16. Radiosensitization produced in vivo by once- vs. twice-weekly 2′,2′-difluoro-2′-deoxycylidine (gemcitabine)
17. Phase I study concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC
18. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis
19. Kinetics of mouse jejunum radiosensitization by 2′,2′-difluorodeoxycytidine (gemcitabine) ant its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells
20. Deoxycytidine kinase activity, mRNA expression and protein content are determinants of radio-enhancement by the nucleoside analogue gemcitabine in human and mouse tumor cells
21. Chemo-radiotherapy: Radiosensitizing nucleoside analogues
22. Phase I study of gemcitabine (G) and high-dose thoracic radiation (RT) in stage III non-small-cell Lung cancer (NSCLC)
23. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism
24. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
25. A phase I trial of preoperative gemcitabine and radiotherapy followed by postoperative gemcitabine for patients with Localized, respectable pancreatic adenocarcinoma
26. Phase I study of gemcitabine, 5-FU, and paclitaxel with RT in recurrent or advanced head and neck cancer
27. Differential incorporation of ara-C, Gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells
28. Phase I study of gemcitabine combined with radiotherapy with or without amifostine in patients with locally advanced head and neck caner
29. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model
30. Phase I study of gemcitabine given weekly as short infusion
31. Gemcitabine: Current status of phase I and II trials
32. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine
33. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI matignancy: A phase I/II study
34. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro
35. Radiosensitization of pancreatic cancer cell by 2′,2′-difloro-2′-deoxycytidine
36. Delayed radiosensitization of human colon cardnoma cells after brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
37. Radiosensitization by gemcitabine
38. Low-dose weekly 24-hour infusion gemcitabine in metastatic and relapsed solid tumors
39. Functinonal nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
40. Maximizing therapeutic gain with gemcitabine and fractionated radiation
41. Phase I trial of three-hour infusion gemcitabine (Gem) (days 1, 8, 15 every 28) in refractory, heavily pretreated (HP) advanced solid tumors
42. Gemcitabine (G) in combination radiation therapy (RT) in stage III-IV pancreatic cancer: First results of a current phase I study
43. Radiosensitizing nucleosides
44. A phase I study of gemcitabine (Gem) in combination with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer
45. Gemcitabine, cisplatin and radiotherapy in squamous cell carcinoma of the head and neck
46. Enhancement of tumor response in vivo by gemcitabine
47. Radiation enhancement by Gemcitabine-mediated cell cyde modulations
48. Effekt von Gemcitabine (in vitro) in abhängigkeit voto zeitabstand der inkubation zur folgenden bestrahlung
49. Radiation enhancement of Gemcitabine in two human squamous cell carcinoma cell lines
50. Verstärkung der radiotherapeutischen wirkung auf hela-zellen durch gemcitabine
51. Multimodale therapie des fortgeschrittenen inoperablen ösophaguskarzinoms
52. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine
53. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial
54. Study of concurrent gemcitabine and radiotherapy in locally advanced stage III B cervical cancer
55. Gemcitabin - Pharmakologisches profil und klinische anwendung
56. Meta-analysis of thoracic radiotherapy for small-cell lung cancer
57. Gemcitabine: Metabolism, mechanism of action and self-potentiation
58. Prolonged infusion of gemcitabine, a preliminary report of a phase I study
59. Difluorodeoxycidine (dFdC) - gemcitabine: A phase I study
60. Chemoradiation therapy with gemcitabine (Gem) in advanced pancreatic cancer
61. Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma
62. Gemcitabine: Its role in radiosensitization and cell cyde progression with two human breast carcinoma cell lines
63. Preoperative radiation with concurrent 5-Fluorouracil for locally advanced T4-primary rectal cancer
64. Concurrent cisplatin-base radiotherapy and chemotherapy for locally advanced cervical cancer
65. The effect of 2′,2′-difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity
66. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
67. Gemzar″ (gemcitabine) with thoracic radiotherapy - A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
68. Anal cancer: Multimodal therapy
69. Metabolism of 2′,2′-Difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
70. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selctive bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 989-03
71. Pilot trial of concurrent gemcitabine (Gem) and radiotherapy as a bladder preservation strategy
72. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in respectable rectal cancer
73. Gemcitabine - A major advance?
74. A phase IB study of gemcitabine (Gem) and concurrent radiotherapy (RT) in advanced carcinoma of the cervix
75. Phase I/II study of gemcitabine combined with cisplatin weekly and concurrent thoracic MV-radiotherapy for patients with stage IIIA/B non-small-cell lung cancer (NSCLC)
76. A randomised phase II study of gemcitabine or paclitaxel or vinorelbine wih cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small-cell lung cancer (NSCLC) (CALGB Study 9431)
77. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancers: A randomized multicenter study
78. Low-dose gemcitabine with radiotherapy in advanced head and neck and thyroid tumors: A phase II study
79. Radiochemotherapy including gemcitabine and 5-fluorouracil for treatment of locally advanced pancreatic cancer
80. Phase I trial of gemcitabine (Gem) combined with radiation (XRT) for the treatment of locally advanced Pancreatic aclenocarcinoma
81. A phase I trial of radiation therapy (RT) plus concurrent fixed dose amifostine (Ami) with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer
82. Phase I trial of concurrent gemcitabine (G) plus chest radiotherapy (XRT), followed by consolidation systemic chemotherapy with G plus dsplatin (CDDP), for patients with stage III and medically inoperable stage II non-small-cell lung cancer